altRx: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of altRx’s website, https://www.altrx.com, FDA Establishment Identifier (FEI) 3044175714, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “altRx” on the pictured label, suggesting altRx is the compounder of those drugs when in fact it is not.”

2. 2

   ““GLP-1s are clinically proven medications….””

3. 3

   ““…clinically proven weight loss.””

4. 4

   “Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

altrx.com returned a live storefront when we checked in August 2026, leading with a summer promotion, a headline monthly price for its GLP-1 and GLP-1 + GIP programmes and a claim to be the most affordable such programme. We did not review every page on the site.

Worth stating plainly, because it would be easy to imply otherwise: FDA quoted no price copy from this company. The letter is about two fragments of the phrase "clinically proven" and about whose name is on the vial, and it makes no finding about whether the advertised price is accurate, sustainable or fair. That matters here more than elsewhere, because altRx sells on price harder than anyone else in this batch — a headline monthly figure and a claim to be the cheapest programme of its kind. Those are two separate questions, and this letter only answers the first. What it does tell you is that the evidence language wrapped around the price is not a regulatory credential, and that the company whose brand is on the label is not, on FDA's account, the one that compounded the contents. A genuinely low price is a reason to look closer at both, not a reason to skip the check.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence altRx failed to respond.